This makes a ton of sense. Have to review those patent arguments but if they tested each, it is pretty obvious what happened. The interesting thing is that these days, these big pharma's don't waste money like they used to on R&D like this. Much easier to just buy a company like Elite, Acura, etc...
"Just figured something out. You are right about the patents and Elite knew what Purdue didn't know. That using NE30 to sequester the Naltrexone was the only choice. Purdue recommended using different polymers but included NE30 in their list of possibles.
However under independent testing the NE30 was far superior an the only logical choice to use. The findings were so surprising that it formed the very basis for the United States Patent Office agreement.
The recommended Purdue Polymers seqestered in a diagnal linear fashion. However Elite's tech changed dramatically at a certain point based on less coating then the Purdue recommended. Instead of a linear gradual increase, Elite's tech would sequester the Naltrexone with a graph, that shoots dramatically north at the 24 hour mark. Purdues recommended Polymer continued the linear path and continued to leak naltrexone through all the testing ranges where Elite's shut down leakage early in the graph.
Purdue didn't know nor would someone skilled in the ART, that NE30 had special properties in sequestering Naltrexone. This is all in the Patent examiner notes for the approved patent. You can read it for yourselves.
So Purdue didn't know or thought they could overcome their inferior formulation and never were able too. Instead moving on to a hard shell product they likely didn't know could be defeated in a microwave or oven."